Pharmacokinetics and Inflammatory-Fluid Penetration of Moxifloxacin following Oral or Intravenous Administration
Authors:
- 1 June 1999
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (6) , 1508-1510
Abstract
A single 400-mg oral or intravenous (i.v.) dose of moxifloxacin was given to each of eight healthy male volunteers, and 6 weeks later the dose was administered by the other route. The concentrations of the drug in plasma, cantharidin-induced inflammatory fluid, and urine were measured over the subsequent 24 h. The mean maximum concentrations observed in plasma were 4.98 μg/ml after oral dosing and 5.09 μg/ml after i.v. dosing. The mean maximum concentrations attained in the inflammatory fluid were 2.62 and 3.23 μg/ml, respectively. The mean elimination half-lives from plasma were 8.32 and 8.17 h, respectively. The overall penetration into the inflammatory fluid was 103.4 and 104.2%. Over 24 h 15% of the drug was recovered in the urine when administered by either route.Keywords
This publication has 7 references indexed in Scilit:
- Pharmacokinetics, Safety, and Tolerability of Ascending Single Doses of Moxifloxacin, a New 8-Methoxy Quinolone, Administered to Healthy SubjectsAntimicrobial Agents and Chemotherapy, 1998
- In vitro activity of BAY 12-8039, a new fluoroquinoloneAntimicrobial Agents and Chemotherapy, 1997
- In vitro Activity of BAY 12-8039, a New 8-MethoxyquinoloneChemotherapy, 1996
- Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219)Antimicrobial Agents and Chemotherapy, 1996
- The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg iv and 750 mg poJournal of Antimicrobial Chemotherapy, 1994
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993
- Safety Overview: Toxicity, Adverse Effects and Drug Interactions1988